Hologic inks $6.2B deal to buy Cytyc

Analysts were voicing their approval for Hologic's newly announced $6.2 billion deal to buy Cytyc, with one saying that the buyout would create the premier women's health company. Hologic is buying the Marlborough, MA-based maker of women's health products for $46.46 a share, well ahead of the $35.05 per share close on Friday. The buyout gives Hologic a cervical cancer test that earned $289 million last year along with a therapy to control menstrual bleeding. The cash and stock deal was also applauded because of the cost-savings a merged operation could offer. The combined company will be a big player in advanced technology related to women's health.

- here's the AP report on the buyout

Related Story:
Cytyc buys Adeza for $452 million Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.